Fresenius SE & Co KGaA
XETRA:FRE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.54
34.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fresenius SE & Co KGaA
Fresenius SE & Co KGaA
Cash Equivalents
Fresenius SE & Co KGaA
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Cash Equivalents
€1.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
69%
|
|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Cash Equivalents
€1.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
50%
|
CAGR 10-Years
62%
|
|
|
Vita 34 AG
XETRA:V3V
|
Cash Equivalents
€14.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
16%
|
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Synlab AG
XETRA:SYAB
|
Cash Equivalents
€2.1m
|
CAGR 3-Years
-87%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fresenius Medical Care AG
XMUN:FME
|
Cash Equivalents
€1.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
50%
|
CAGR 10-Years
62%
|
|
Fresenius SE & Co KGaA
Glance View
Fresenius SE & Co KGaA is a global healthcare group rooted in Germany, dedicated to providing high-quality medical services and products to patients worldwide. Founded in 1912, the company has grown into a diverse organization with a strong focus on life-saving therapies in renal care, hospital services, and pharmaceutical manufacturing. With its subgroups—Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed—the company operates across different segments that collectively support its vision of enhancing patient outcomes, improving quality of care, and meeting the increasing demand for healthcare services in an aging global population. By leveraging an extensive network of healthcare facilities, innovative product pipelines, and a commitment to sustainability, Fresenius positions itself as a leader in the dynamic healthcare landscape. For investors, Fresenius SE & Co KGaA represents an opportunity to engage with a stable yet growth-oriented enterprise. The company has consistently demonstrated resilience, even amidst market fluctuations, reflecting a strong financial foundation and strategic leadership. With the global healthcare market projected to expand, driven by an increase in chronic diseases and the need for advanced medical solutions, Fresenius is well-poised to capture significant market share. Its focus on innovation, particularly in personalized medicine and digital health, underscores a forward-thinking approach that aligns with evolving patient needs. As a long-term investment option, Fresenius' commitment to enhancing healthcare accessibility and efficiency not only offers the potential for financial returns but also contributes positively to global health outcomes, making it a compelling choice for investors looking for a balance of impact and profit.
See Also
What is Fresenius SE & Co KGaA's Cash Equivalents?
Cash Equivalents
1.5B
EUR
Based on the financial report for Sep 30, 2024, Fresenius SE & Co KGaA's Cash Equivalents amounts to 1.5B EUR.
What is Fresenius SE & Co KGaA's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
69%
Over the last year, the Cash Equivalents growth was 36%. The average annual Cash Equivalents growth rates for Fresenius SE & Co KGaA have been -15% over the past three years , 31% over the past five years , and 69% over the past ten years .
You don't have any saved screeners yet
